Promoting Independence in Dementia (PRIDE): A Feasibility Randomized Controlled Trial by Csipke, Emese et al.
O R I G I N A L  R E S E A R C H
Promoting Independence in Dementia (PRIDE): 
A Feasibility Randomized Controlled Trial
This article was published in the following Dove Press journal: 
Clinical Interventions in Aging
Emese Csipke 1 
Aisha Shafayat 2 
Kirsty Sprange 2 
Lucy Bradshaw2 
Alan A Montgomery2 
Reuben Ogollah 2 
Esme Moniz-Cook 3 
Martin Orrell 4
1Division of Psychiatry, University 
College London, London, UK; 
2Nottingham Clinical Trials Unit, 
University of Nottingham, Nottingham, 
UK; 3Faculty of Health Sciences 
University of Hull, Hull, UK; 4Institute of 
Mental Health, University of Nottingham, 
Nottingham, UK 
Background: There is a need for interventions to foster and maintain independence for 
people with dementia to support community living, improve morale, and reduce stigma. We 
investigated a social intervention to promote living well and enhance independence for 
people with mild dementia.
Methods: In this two arm parallel group, feasibility RCT at six sites in England, participants 
were randomized (1:1) to the PRIDE intervention (encompassing social, physical, and 
cognitive domains supported by a facilitator over three sessions) compared to usual care 
only. The main objective was to determine the feasibility of a main trial with respect to 
measures of recruitment, retention, and adherence to the intervention.
Results: During a 7-month period, 402 people were invited to the trial, 148 were screened 
(37%, 95% confidence interval (CI)=32–42%), 137 were eligible at pre-consent, 94 con-
sented to the trial (69% of those eligible, 95% CI=60–76%), and 92 were randomized (46 to 
each group). Of those allocated to the intervention, 42 (91%) received at least one of three 
intervention sessions. Outcome assessment follow-up visits were completed for 73 partici-
pants at 6 months (79%, 95% CI=70–87%), and this was similar for both groups.
Conclusion: A large multi-center trial of the PRIDE intervention in community-dwelling 
people with mild dementia is feasible using systematic recruitment strategies. The interven-
tion was successfully delivered and well received by participants. Findings from this study 
will be used to refine the design and processes for a definitive RCT.
Trial Registration: ISRCTN, ISRCTN11288961, registered on 23 October 2018.
Keywords: dementia, feasibility trial, randomized controlled trial, psychosocial intervention
Background
People with dementia lose independence for many reasons, such as neurological 
deterioration, reduced living skills, or negative social consequences, such as stigma, 
social exclusion, and disempowerment. Receiving specialist support soon after diag-
nosis may facilitate independence in early stage dementia. Family and friends may also 
inadvertently contribute to a reduced sense of autonomy in people with dementia by 
a lowered set of expectations, and well intentioned “taking over” of decision-making 
and responsibilities in order to support their relative.1 Fundamental concerns for people 
with dementia include loss of power in social relationships, the need to maintain active 
roles outside their immediate social networks, and a dearth of information on diagnosis, 
prognosis, and post-diagnostic support services. Both the UK government and the EU 
Joint Program for Neurodegenerative Disease Research have underscored the need for 
high quality psychosocial interventions, to support the growing post-diagnostic needs 
of people with dementia.2
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The Promoting Independence in Dementia (PRIDE) 
program was developed as a post-diagnostic social 
intervention3,4 to support independence and quality-of- 
life for people with early stage dementia, so that they 
could live well and as independently as possible in the 
community. The PRIDE intervention includes the princi-
ples of self-management as applied to the treatment of 
chronic conditions,5 including teaching the individual 
how to manage their condition and identify solutions spe-
cific to their needs.6 Strategies can include decision- 
making, identifying and using available resources, pro-
blem-solving, and being an active participant in choices 
about care, in partnership with healthcare professionals.7,8 
PRIDE promotes social inclusion, harnesses the support of 
the person’s social network, and facilitates engagement in 
stimulating cognitive, physical, and social activities. The 
intervention is aimed at those with mild dementia who are 
likely to have minor difficulties with daily living activities. 
It was manualized using the conceptual frameworks and 
associated mechanisms of action that were identified 
within the research program.9 It allows individualized 
tailoring according to the person’s needs and circum-
stances using co-production approaches to develop the 
intervention.
Previous groundwork involved a mixed-methods non- 
randomized, pre–post feasibility study, conducted at four 
sites.10 This found that the intervention was acceptable 
where 73% completed all three sessions. However, recruit-
ment and delivery within the voluntary sector was not 
effective. The present feasibility study was delivered in 
an alternative setting, utilizing NHS services for delivery 
of the intervention. We also wished to examine whether 
the variable recruitment rates we noted previously could 
be improved using site-specific requirements. This infor-
mation about availability of intervention facilitators and 
site-based requirements for recruitment is of key impor-
tance for determining the feasibility of a future large-scale 
definitive RCT.
The aim of this study was to investigate the feasibility of 
the PRIDE intervention, within a randomized controlled 
design to inform a future large scale definitive RCT of the 
clinical and cost effectiveness. This study examined in detail 
screening, recruitment, and follow-up rates, and the potential 
of clinical outcome measures within a RCT design, as we were 
interested in completion rates of follow-up data, particularly 
for those not allocated to the intervention group. The 
embedded qualitative study, fidelity assessment, and data to 
inform the cost-effectiveness analysis will be reported 
elsewhere.
Methods/Design
This PRIDE randomized feasibility study was designed as 
a two arm parallel group multi-center study with partici-
pants individually allocated on a 1:1 ratio to usual care or 
usual care plus the PRIDE intervention. It also included an 
embedded qualitative process evaluation (see protocol11 
for design and methods).
Participants
Recruitment took place in six NHS sites across England, 
with participants identified via the NHS, Joint Dementia 
Research (JDR; an online research register) and self- 
referral. Participants were eligible if they were within the 
selected site-catchment area; aged over 18 years; met the 
Diagnostic and Statistical Manual of Mental Disorders- 
Fourth Edition criteria for dementia of any type; were able 
to provide informed consent and engage in the intervention 
in the opinion of the investigator (or designee); were able to 
read/communicate in English; and were not living in institu-
tional care. In addition, the participant must have had mild 
dementia, defined as a score of 0.5 or 1 on the Clinical 
Dementia Rating (CDR) Scale, which was assessed at the 
baseline visit after consent. Participants were able to take 
part with or without a supportive other (eg, carer). If taking 
part, the supporter was eligible if they were aged 18 or over; 
able to engage with and participate in the intervention; and 
able to provide informed consent and read and communicate 
verbally in English. After identification, a member of the site 
research team contacted the potential participant to confirm 
initial eligibility and to arrange a baseline assessment. At the 
home visit, the researcher explained the study, obtained 
written informed consent, and collected baseline data includ-
ing the CDR scale12 to confirm eligibility.
Follow-up visits were conducted at 3 and 6 months post- 
randomization in the participant’s home by a site research 
team member blind to group allocation. Questionnaires for 
supporters were either completed at the visit if the supporter 
was present or left with a prepaid envelope for the supporter 
to return to the coordinating center.
Facilitation
Training
Training by the research team involved a 1-day session 
developed through co-production and consultation with 
voluntary sector dementia advisors and NHS memory 
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clinic nurses. The theories underlying the intervention 
were provided, followed by group work, role play, and 
discussion. Facilitators all had a background of working 
with dementia. Trainers were available throughout the 
study for continued support.
Usual Care and Intervention 
All participants received the services usually available to 
people with dementia at the participating sites. In addition, 
participants allocated to the intervention arm received the 
PRIDE intervention.4 The three-session intervention is 
delivered by trained intervention facilitators. Each session 
lasts between 1–2 hours conducted in a venue selected by 
the participant, usually their own home. Working together, 
the intervention provider and participant develop 
a personalized profile for the person with dementia. This 
is followed by a collaborative approach to planning for 
doing activities that are important to the person with 
dementia. These plans are reviewed in subsequent sessions 
and modified if necessary. A paper manual guides the 
intervention and includes signposting to information and 
resources, and an electronic version was also available 




The primary outcome of this study was the feasibility set 
within an RCT design to explore further what is required 
for delivery of large scale definitive RCT of the PRIDE 
intervention. The objectives and outcomes are shown in 
Table 1.
Clinical Outcomes
Nine clinical outcomes measures for participants, 
described in Table 2 to collect data on domains recom-
mended to evaluate psychosocial interventions in 
dementia,13,14 were collected at the baseline, 3, and 6 
months. These outcomes covered Activities of Daily 
Living,15 Quality-of-Life (DEMQoL16), EQ5D-5L,17, 
Mood (GDS-1518), Cognition (SMMSE19), Wellbeing 
(CASP20), Quality of relationships (IPAQ-O21), and 
Positive emotions (PPOM22). In addition, participants 
were asked to provide a rating of their perceived change 
in wellbeing and independence compared to the start of the 
study (global change) to be used to explore the respon-
siveness to change of the clinical outcome measures. 
Supporters were similarly asked to provide a rating of 
their perceived change for the person with dementia in 
wellbeing and independence. Questionnaires were read 
out to participants to ensure consistency and promote 
inclusiveness for those who found reading text difficult.
Sample Size
As this was a feasibility study, a formal sample size 
calculation for between group comparisons of a primary 
outcome was not appropriate. A target sample size of 75– 
80 participants was set over the recruitment period to 
establish recruitment capability of the range of participat-
ing services. Seventy-five participants at randomization 
allowed estimation of recruitment with a margin of error 
(half-width of 95% confidence interval) of around 8 per-
centage points, and retention of 12 percentage points.
Randomization
Participants were allocated at the individual level to inter-
vention or control on a 1:1 ratio using a minimization 
algorithm with a probabilistic element, created by the 
Nottingham Clinical Trials Unit (NCTU). The minimiza-
tion variables were site, gender, age (<80 or ≥80) and 
medication for dementia (any vs none). The investigator 
or “authorized designee” randomized participants, follow-
ing completion of the baseline assessments, using 
a remote, internet-based randomization system. 
Following randomization, participants were notified of 
their treatment allocation by an unblinded member of the 
research team. Researchers remained blind to allocation.
Statistical Analyses
Data analysis were primarily descriptive. All analyses 
were documented in a Statistical Analysis Plan which 
was finalized prior to database lock. Feasibility outcomes 
were estimated using descriptive statistics (with 95% con-
fidence intervals – CI – if relevant) and included recruit-
ment rates, follow-up rates in both arms of the trial, 
missing data, and intervention adherence. Demographic 
and clinical characteristics at baseline were summarized 
in the two allocated groups. Clinical outcomes were sum-
marized descriptively for participants with outcome data 
regardless of adherence with the allocated intervention.
Three clinical outcomes, the Lawton Instrumental 
Activities of Daily Living (IADL) scale, quality-of-life 
using the DEMQoL and wellbeing using Control, 
Autonomy, Self-realization, and Pleasure scale (CASP, 
scored from both 19-item and 12-item version), were 
chosen as candidate primary outcomes to evaluate their 
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Table 1 Feasibility Objectives and Outcomes
Feasibility Objectives Feasibility Outcomes
1. Determine the feasibility of recruitment to a large-scale RCT (a) Aggregate data on potential participants within NHS services
(b) Number of patients assessed for eligibility/consented/randomized
(c) Number and proportion of potential participants identified through 
NHS services, Join Dementia Research, and by self-referral who are 
eligible
(d) Reasons for non-inclusion/non-eligibility
(e) Monthly recruitment rate per site
(f) Barriers and facilitators to recruitment (Interviews/focus groups)
2. Refine the eligibility criteria for a future definitive RCT (a) Number of screening failures for eligibility, post-consent
(b) Participant and facilitator report (Interviews/focus groups)
3. Determine the acceptability to patients/clinicians of randomization (a) Proportion of eligible patients that consent to randomization
(b) Reasons for non-consent
(c) Participant and facilitator report (Interviews/focus groups)
4. Determine the relevance and acceptability to patients/clinicians of 
the trial intervention
(a) Premature discontinuation or non-attendance of treatment and 
reasons
(b) Feedback from participants and site staff delivering the intervention
(c) Participant and facilitator report (Interviews/focus groups)
5. Determine the acceptability to patients/clinicians of the trial 
procedures
(a) Proportion of approached NHS sites that agree to participate in the 
trial and reasons for non-participation
(b) Proportion of eligible patients that consent to randomization
(c) Reasons for non-consent
(d) Withdrawals and losses to follow-up and reasons
(e) Feedback from participants and staff (Interviews/focus groups)
6. Assess the ability of NHS sites to deliver the intervention (a) Measures of the feasibility of delivering the PRIDE intervention within 
NHS settings: number/grade/experience of staff within the service, 
staff turnover, and time to treatment initiation
(b) Measures of the recruitment and retention of PRIDE facilitators dur-
ing the study treatment period
(c) Barriers to treatment delivery per protocol (Interviews/focus groups)
7. Assess training and support needs for NHS staff delivering the 
intervention
(a) Feedback on training delivered (Interviews/focus groups)
(b) Support offered/accepted (eg, log of calls and emails to central sup-
port lines)
8. Evaluate treatment fidelity when delivered through NHS services (a) Measures of treatment fidelity including: adherence to intervention 
manual and uptake of activities
(b) Feedback from participants and staff (Interviews/focus groups)
9. Determine the services and interventions provided as usual care 
and evaluate methods for measuring this
(a) Post-diagnostic care pathway
(b) Services available
(c) Uptake of services
10. Assess follow-up and outcome completion rates (a) Response rate to follow-up assessment
(b) Questionnaire completion rates
(c) Amount of missing questionnaire data at item and scale levels
11. Determine the relevance and acceptability of a range of clinical 
outcome measures and selection of the primary outcome for the 
main trial
(a) Completion rates and reasons for non-completion/missing data
(b) Estimates of clinically important differences, variance, and sensitivity 
to change for the clinical outcome measures
(c) Direct questions to participants regarding relevance of measures
(Continued)
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responsiveness and minimal important change (MIC);25 
against the global change questions at 6 months (see 
Supplementary Methodology 1).
It was not an objective of this feasibility study to obtain 
definitive estimates of the intervention effect on clinical 
outcomes as it was not powered to do so. However, differ-
ences in means between groups (with CIs) for the candi-
date primary outcomes described above at 6 months were 
calculated using linear mixed models, adjusted for the 
minimization variables with a random effect for the 
recruiting site, to show the possible range of treatment 
effects. Adjusted differences in means are presented with 
95%, 85%, and 75% CIs in forest plots to explore the 
strength of the preliminary evidence.26
Results
Sites and Recruitment
Fifty-three sites were approached through a national 
Memory Services register, of which 29 (55%) expressed 
an interest and 19 (36%) returned the study eligibility 
questionnaire. Of these, 12 (63%) met the eligibility cri-
teria and six were selected. Sites were geographically 
spread and covered urban and rural areas, a wide socio- 
economic distribution, and varied in terms of the size of 
the populations they served. Overall, 46 research staff 
were involved in the study, ranging from three to 12 per 
site. Nineteen staff were trained to be facilitators, and 
comprised of nurses, occupational therapists, clinical 
researchers, and assistant psychologists.
The sites opened to recruitment between 
November 2018 and February 2019. Figure 1 summarizes 
the participant flow into the trial. Of the 402 people 
invited, 148 were screened (37%, 95% CI=32–42%), 
with a mean age of 77 years (SD=8.1) and half were 
female. Of those screened, 137 (93%) were eligible pre- 
consent, 94 consented to the trial (69% of those eligible, 
95% CI=60–76%), and 92 were randomized (67%, 95% 
CI=59–75%), 46 to each arm. Following screening, one 
site contributed to most of the 54 “non-consenting” parti-
cipants and, of those, the majority could not be contacted 
again after the initial approach (n=23) or declined to 
participate (n=10). The number of participants randomized 
per site ranged from 11–22, with a mean of 2.6 partici-
pants randomized per month.
Randomized participants had a mean age of 78 
(SD=8.0), half were female, most were of white ethnicity 
(93%), and approximately two thirds had Alzheimer’s type 
dementia (Table 3). Baseline characteristics were in gen-
eral well balanced across the two groups, although slightly 
more participants in the PRIDE intervention group were 
married (or had a partner) and lived with others compared 
to the usual care group (Table 3). Around two thirds of 
participants chose to take part with a supporter and the 
majority of supporters were a spouse or partner (Table 3).
Of those allocated to the intervention, 42 (91%) 
received at least one intervention session, with 42 (91%) 
attending the first session, 34 (74%) the second, and 33 
(72%) the third session. The main reason for non- 
attendance at sessions was withdrawal from the study, 
occurring at session 2 (n=5) and session 3 (n=6). The 
paper manual was used for all participants, apart from 
one participant who used both the paper and electronic 
versions.
Outcome assessment visits were completed for 78 par-
ticipants (85%, 95% CI=76–91%) at 3 months and 73 
(79%, 95% CI=70–87%) at 6 months and completion 
Table 1 (Continued). 
Feasibility Objectives Feasibility Outcomes
12. Evaluate the utility and acceptability of resource use question-
naires for use in an economic evaluation alongside a future RCT
(a) Completion rate and reasons for non-completion/missing data
13. Comparative micro-costing of PRIDE intervention and usual care (a) Staff time and resources for delivery of PRIDE intervention
(b) Other service use
14. Estimate the sample size required for a definitive study (a) Primary outcome selection
(b) Variability in the outcome
(c) Withdrawals and losses to follow-up
15. Determine the resources required for a full trial (a) Sample size, recruitment rate (number of sites/recruitment period), 
staffing and resources (for recruitment, treatment and follow-up)
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Table 2 Summary of the Clinical Outcome Measures
Outcome Measures Scale, Description, and Source Derivation of ScoresA
Participants
Activities of Daily Living ● Measured using the Lawton Instrumental Activities of Daily 
Living (IADL) Scale15
● Performance is measured across eight domains
● Each domain has between three and five response options 
describing ability. These are scored as 0 (less able) or 1 (more 
able)
● Domain scores summed to produce summary score from 0 (low 
function) to 8 (high function)
Health-related quality- 
of-life
● Measured using EuroQoL Quality-of-Life Questionnaire – 5 
Domains, 5 Levels17
● Consists of two parts: a descriptive system and a visual analog 
scale (VAS) asking about health on that day
● The 5 level descriptive system used as part of the health 
economic analysis and VAS summarized in the quantitative 
analysis of the clinical outcomes
● VAS scores range from 0 (worst health can imagine) to 100 (best 
health can imagine)
Quality-of-life ● Measured using DEMQoL16
● Assesses five domains of quality-of-life including health and 
well-being, cognitive functioning, social relationships and self- 
concept
● Scale consists of 28 items about the last week with four response 
options (a lot, quite a bit, a little, and not at all)
● Items are scored as 1=a lot, 2=quite a bit, 3=a little, and 4=not 
at all, apart from five positive questions, which are scored in 
reverse
● Items are summed to produce a total score ranging from 28–112, 
higher scores indicating better quality-of-life
● Missing items are imputed with person-specific mean of com-
pleted items provided at least 50% of items are complete (ie, 14 
items)
Mood ● Measured using the Geriatric Depression Scale (GDS) – short 
form18
● 15-items about the last week with responses of yes or no
● Items scored as 1 when response indicates depression and 0 
otherwise (10 items indicate the presence of depression when 
answered positively, and five items when answered negatively)
● Item scores summed to produce a total score ranging from 0–15, 
with higher scores indicating more severe depression
Cognition ● Measured using the Standardized Mini Mental State Exam 
(S-MMSE)19
● Brief assessment of cognition testing orientation (time and 
place), repetition, verbal recall, attention and calculation, lan-
guage and visual construction
● The total test score is the sum of the correct responses ranging from 
0–30, with a lower score indicating more cognitive impairment
● An adjusted score can be calculated for people who are physi-
cally unable to do some of the tasks on the MMSE (IHPA 
Australia)
Wellbeing ● Control, Autonomy, Self-realization, and Pleasure (CASP) 
questionnaire20
● Assesses quality-of-life in older people across four domains; 
control, autonomy, pleasure, and self-realization
● 19 items with four response options (often, sometimes, not 
often, and never)
● Items scored on a 4-point Likert scale as shown on the CASP 
website (https://casp19.com/casp-scoring-and-properties/).
● Items scores summed to produce a total score ranging from 0– 
57, with higher scores indicating better quality-of-life.
● The 12 item version of the CASP also used as this has been found to 
have a better factor structure for people with dementia than the 19 
item.19 In the 12 item version, items 3 (control subscale), items 6 and 
8 (autonomy subscale), items 13 and 14 (pleasure subscale), and 
items 16 and 17 (self-realization subscale) are not used
(Continued)
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Table 2 (Continued). 
Outcome Measures Scale, Description, and Source Derivation of ScoresA
Quality of relationships ● Measured using Impact on Participation and Autonomy 
Questionnaire for older people (IPAQ-O) social relations 
subscale21
● Social relations subscale has five items with five response items
● The response options on the PRIDE CRF were very good, good, 
fair, poor, and very poor from the original IPAQ23 rather than 
amended response options for the IPAQ-O (totally agree, partly 
agree, neither agree nor disagree, disagree, and totally disagree)
● The response options were scored as on the original IPAQ: very 
good=1, good=2, fair=3, poor=4, and very poor=5
● Item scores summed to produce a total score ranging from 5– 
25, with higher score indicating more restriction in participation
Positive emotions ● Measured using the Positive Psychology Outcome Measure 
(PPOM)22
● Two subscales: hope and resilience
● 16-item scale measuring aspects of positive psychology with an 
eight item hope subscale and an eight item resilience subscale
● Each item is rated on a 5-point Likert scale (0=not true at all, 
1=rarely true, 2=sometimes true, 3=often true, 4=true nearly all 
the time)
● Items scores summed to produce a total score ranging from 0– 
64 and subscale scores ranging from 0–32, higher scores indicate 
better wellbeing
Social engagement ● Measured using the number of social contacts and leisure 
activities in the preceding 2 weeks
Questions asked:
● How many times over the last 2 weeks have you met up with 
friends or family? (eg, family or friends visiting, you visiting them, 
attending a social club)
● How many times over the last 2 weeks have you participated in 
any leisure activities? (eg, hobbies)
Global change in 
wellbeing and 
independence at 3 and 6 
months
● Participants were asked to provide a rating of their perceived 
change using a 5-point ordinal scale.
Questions asked:
● Compared to 3/6 [depending on time since randomization] 
months ago when you started in the PRIDE study, how would 
you rate your general wellbeing now? Response options: much 
better, a bit better, no change, a bit worse, much worse
● Compared to 3/6 [depending on time since randomization] 
months ago when you started in the PRIDE study, how inde-
pendent do you feel now? Response options: much more inde-
pendent, a bit more independent, no change, a bit less 
independent, much more independent
● Supporters were asked to independently provide a rating of 
their perceived change for the person with dementia from their 
perspective, during the course of the study, using the same 
5-point ordinal scale
Questions asked:
● Compared to 3/6 months ago [depending on time since rando-
mization] when your friend/relative started in the study, how 
would you rate their general wellbeing now?
● Compared to 3/6 months ago [depending on time since rando-
mization] when your friend/relative started in the study, how 




Measured using the EuroQoL Quality-of-Life Questionnaire – 5 
Domains, 5 Levels
● Consists of two parts: a descriptive system and VAS
● The 5 level descriptive system used as part of the health 
economic analysis and VAS summarized in the quantitative 
analysis of the clinical outcomes
● VAS scores range from 0 (worst health can imagine) to 100 (best 
health can imagine)
Notes: AFor missing data within questionnaires, tool-specific guidance was used to derive scores if available. Otherwise missing items were imputed by the participant mean 
of the completed responses (rounded to one decimal place) in order to derive scores.24 BMood measured using the General Health Questionnaire was listed as an outcome 
for supporters in version 1.0 (Sept 18, 2018) of the protocol, however this was removed in version 2.0 (Dec 20, 2018) to reduce the burden on participant and supporters in 
completing questionnaires and was not collected for any supporters.
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Figure 1 Participant flow diagram.
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was similar in the two groups (Figure 1). Outcome assess-
ment visits were not completed due to withdrawal of 
consent from the trial and at 6 months due to being unable 
to organize a visit within the time frame (Figure 1). 
Participants who did not complete the visit at 6 months 
were slightly older than those completing the visit 







Age at randomization (years)
Mean [SD] 78.6 [7.1] 77.3 [8.9] 78.0 [8.0]
Median [25th, 75th centile] 79 [74, 85] 78 [72, 84] 78 [73, 84]
Min, max 56, 90 51, 93 51, 93
≥80 21 (46%) 20 (43%) 41 (45%)
Gender
Male 23 (50%) 23 (50%) 46 (50%)
Female 23 (50%) 23 (50%) 46 (50%)
Ethnicity
White 42 (91%) 44 (96%) 86 (93%)
Black 1 (2%) – 1 (1%)
Asian 2 (4%) 2 (4%) 4 (4%)
Mixed 1 (2%) – 1 (1%)
Educational attainment
Primary – – –
Secondary 31 (67%) 26 (57%) 57 (62%)
Higher 15 (33%) 19 (41%) 34 (37%)
Not known – 1 (2%) 1 (1%)
Living arrangements
Lives alone 15 (33%) 9 (20%) 24 (26%)
Lives with others 31 (67%) 37 (80%) 68 (74%)
Marital status
Single/divorced/widowed/separated 16 (35%) 10 (22%) 26 (28%)
Married/with partner 30 (65%) 36 (78%) 66 (72%)
Facilities available for use of web-based manual (ie, computer and internet 
access)
17 (37%) 16 (35%) 33 (36%)
Type of dementia
Alzheimer’s Type 31 (67%) 28 (61%) 59 (64%)
Vascular 10 (22%) 9 (20%) 19 (21%)
Lewy body – 2 (4%) 2 (2%)
Mixed 3 (7%) 5 (11%) 8 (9%)
Not known 1 (2%) 1 (2%) 2 (2%)
Other (frontotemporal dementia) 1 (2%) 1 (2%) 2 (2%)
Medication taken for dementiaA 32 (70%) 32 (70%) 64 (70%)
Clinical Dementia Rating Scale score
0.5 (very mild) 28 (61%) 35 (76%) 63 (68%)
1 (mild) 18 (39%) 11 (24%) 29 (32%)
Supporter consented to participate 34 (74%) 30 (65%) 64 (70%)
Spouse/partner 23 24 47
Son/daughter 9 5 14
Friend or another relative 2 1 3
Notes: Data are N (%) unless otherwise indicated. AMedication for dementia include any of the following: Donepezil Hydrochloride, Rivastigmine, Memantine 
Hydrochloride, and Galantamine.
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(mean=80 years [SD=7] vs mean 77 years [SD=8]). At the 
visits, completion of the clinical outcomes was high. All 
assessments were completed sufficiently to derive a score 
apart from the standardized mini mental state exam 
(sMMSE) which was not fully completed by two partici-
pants at 3 months and four participants at 6 months, one 
participant refused to do the PPOM at 6 months and there 
was insufficient time for completion of the sMMSE and 
CASP at the 6 month visit for one participant. Between 
80% and 90% of participants at each time point agreed or 
strongly agreed that the questions in the EQ-5D and the 
DEMQoL were relevant to them with between 70% and 
80% agreeing or strongly agreeing for the other measures. 
Of the 64 supporters who consented to the trial, 55 (86%) 
completed the follow-up questionnaire at 3 months and 52 
(81%) at 6 months.
At 6 months, 36% of participants (26/73) rated their 
wellbeing as a bit better or much better compared to when 
they started in the study and 22% (16/73) responded that 
they were a bit more or much more independent (Table 4). 
Supporters responded that participant wellbeing was a bit/ 
much better for 13% (7/52) and that the participant was 
a bit/much more independent for 11% (6/52). The area 
under the ROC curves (AUC) for improvement in well-
being using the participant rating at 6 months according to 
change in baseline in the candidate primary outcomes 
ranged from 0.55–0.74 (Table 5) with the greatest area 
observed for the CASP12. Similar values were observed 
for the AUC using the participant rating of independence 
as the external criterion for improvement. The AUC for no 
decline in independence using the global change question 
was also evaluated in a post hoc analysis with change in 
CASP12 having the greatest AUC for no decline (0.65, 
95% CI=0.48–0.83). All estimates of the minimal impor-
tant change for the candidate primary outcome measures 
shown in Table 6 have wide confidence intervals, although 
estimates in general were fairly similar using either the 
participant or supporter rating of change for each estima-
tion method.
Scores on the clinical outcomes were similar in the two 
groups at all time points (Table 7). In Figure 2, 95% 
confidence intervals for the difference between groups 
include 0 for all of the candidate primary outcome mea-
sures. The 85% and 75% CIs are supportive of small 
differences favoring the intervention group for the IADL, 
however in contrast for the CASP 85% and 75% CIs 
mostly lie below 0 (ie, favoring the usual care group) 
with upper limits between 0 and 1.
Discussion
This feasibility trial demonstrated that it is possible to 
conduct a definitive multi-center randomized controlled 
trial of the PRIDE intervention for people with dementia. 
A key strength of the study was our ability to recruit 
participants across varied sites in terms of local dementia 
service provision. With the exception of one site who 
adopted a wide net approach to screening, the retention 
rate from screening through to randomization was high, 
indicating that the screening procedures worked well and 
wide net approaches to recruitment are not efficient in 
terms of delivery of a trial such as ours. From a variety 
of recruitment methods, face to face invitations via the 
clinic or letters sent by the clinical sites were most suc-
cessful. There was a high attendance rate for those receiv-
ing the intervention with non-attendance due to 
participants withdrawing from the trial, possibly due to 
losing momentum as sessions were spaced over 2 months. 
Across the sites we were able to train an adequate number 
of staff to act as facilitators, and local NHS Clinical 
Research Networks – CRNs – were very helpful and 
effective in sourcing research staff to recruit and collect 
data for this study.
Recruitment of study sites and participants is the key to 
the success of any trial.27 Following our field testing prior 
Table 4 Wellbeing and Independence: Participant Rating of Change 
in General Well-Being and Independence at 6 Months Compared to 










Much worse – – –
A bit worse 7 (18%) 6 (17%) 13 (18%)
No change 18 (47%) 16 (46%) 34 (47%)
A bit better 8 (21%) 8 (23%) 16 (22%)
Much better 5 (13%) 5 (14%) 10 (14%)
Independence
Much less independent 2 (5%) – 2 (3%)
A bit less independent 8 (21%) 5 (14%) 13 (18%)
No change 20 (53%) 22 (63%) 42 (58%)
A bit more independent 6 (16%) 4 (11%) 10 (14%)
Much more independent 2 (5%) 4 (11%) 6 (8%)
Note: Percentages use the number of participants completing the questionnaire at 
6 months as the denominator.
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to this feasibility trial, we concluded that stringent site 
selection is important.10 Being clear on what is expected 
of the trial sites themselves enabled recruitment to be 
carried out more smoothly compared with our previous 
study.3 Requiring the sites to identify their own interven-
tion facilitators was also a successful strategy. This was 
because in-house organization meant that time and 
resources could be better managed by the team them-
selves, who also had control over ensuring adequate staff 
were in place throughout the trial. This is vital in a trial 
that is resource heavy both at sites and within the research 
team, and the time required to keep the study on track due 
to the variability of services. Even with each site requiring 
to meet the same criteria, there were differences in site 
configuration and individual approaches, but this demon-
strates a larger trial would be feasible even with variation. 
Maintaining good communication between the research 
team and the sites was required, especially for those with 
less research experience.
There was a high completion rate for all the outcome 
measures indicating that they were feasible to use in both 
arms of the study, and that the overall time taken and 
number of measures included was reasonable. Comparing 
the responsiveness to change of the candidate primary 
outcome measures in terms of wellbeing and indepen-
dence, the CASP12 appeared to perform slightly better 
than the other options including the CASP 19, the IADL, 
and the DemQol. Further work is needed to estimate the 
minimal important change for these outcome measures as, 
due to the sample size in this study, confidence intervals 
for the estimates were wide. Preliminary evidence of the 
effectiveness of the intervention using these three outcome 
measures was, however, conflicting and did not signal an 
effect of the intervention on the CASP measure. 
Interpretation of this data should be treated with caution 
since this was not the main aim of this feasibility study. 
Taking into account the performance of the measures, 
a future trial could substitute the DemQol and the 
CASP19 for related shorter instruments such as the 
CASP-12 and other relevant measures arising from recent 
reviews on outcome measures for studies of this type.27,28
Given that people with dementia think that “in the 
moment” measurement is perhaps more reflective of their 
response to psychosocial interventions,29 there is scope to 
incorporate emerging digital Experience Sampling 
Methods (ESM)30 in a future definitive RCT of the 
PRIDE intervention.
The PRIDE intervention appears to be a useful and 
relevant way to try to improve independence and a range 
of activities for people with early stages of dementia. 
However, although it was popular and easy to use, at this 
stage we do not have a clear idea of the potential clinical 
benefits in practice. Based on this feasibility trial, we are 
now able to design a full scale protocol for a large multi- 
center trial of the PRIDE intervention compared to usual 
care, with some alterations and reductions to the range of 
outcome measures we examined.
Table 5 Responsiveness to Change at 6 Months for Candidate Primary Outcome Measures


















Spearman correlation between change 
from baseline at 6 months and global 
change in wellbeing question
0.19 0.26 0.08 0.22 0.34 0.33 0.40 0.24
Area under the ROC curve for improvers 
in wellbeing according to change from 


















Spearman correlation between change 
from baseline at 6 months and global 
change in independence question
0.17 0.09 −0.08 0.29 0.29 0.49 0.34 0.41
Area under the ROC curve for improvers 
in independence according to change 
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It should be acknowledged, however, that the 
COVID-19 pandemic is likely to have a continued 
impact on care delivered in the community for people 
with dementia, but may also add limitations to what 
people are able to do in terms of activities outside the 
house. We suggest that the PRIDE intervention can be 
delivered with minimal contact in the home and is 
flexible in its tailoring to individual needs, prefer-
ences, and circumstances to be further tailored to indi-
viduals affected by the changes imposed through the 
current COVID-19 epidemic. Although only one parti-
cipant used the online version, since the recent 
COVID-19 epidemic and its strategies for safety, 
many people have resorted to online resources in com-
munication and gaining knowledge. Ongoing work 
from our research team on a refined PRIDE web- 
based solution will allow for tailoring of the PRIDE 
interventions including for those who have become 
further isolated and fearful during and beyond the 
epidemic.
Table 6 Estimates of the Minimal Important Change (MIC) at 6 Months for the Candidate Primary Outcomes Measures
Using Participant Response to Global 
Change Question 
MIC Estimate (95% CI)
Using Supporter Response to Global 
Change Question 
MIC Estimate (95% CI)
Using global change in well-being as anchor
IADL
Between patient score change 0.2 (−0.6 to 1.0) −0.2 (−1.6 to 1.1)
Sensitivity/specificity approach 0.4 (−2 to 2) 0 (−2 to 2)
DEMQoLA
Between patient score change 3.6 (−3.1 to 10.3) 4.6 (−6.7 to 15.8)
Sensitivity/specificity approach 5 (−7 to 18) 12 (0 to 14)
CASP19
Between patient score change 3.5 (0.1 to 6.9) 3.7 (−4.5 to 11.8)
Sensitivity/specificity approach −3 (−3 to 3) 1 (−3 to 7)
CASP12
Between patient score change 2.3 (−0.1 to 4.7) 2 (−4 to 7.9)
Sensitivity/specificity approach 1 (−3 to 3) −3 (−3 to 5)
Using global change in independence as anchor
IADL
Between patient score change 0.6 (−0.4 to 1.6) −0.6 (−2 to 0.8)
Sensitivity/specificity approach 0.4 (−1 to 2) 0 (−2 to 2)
DEMQoLA
Between patient score change Not calculatedA 1.7 (−8.7 to 12.1)
Sensitivity/specificity approach 6 (−4 to 18)
CASP19
Between patient score change 2.6 (−1.7 to 6.8) 2.6 (−3.8 to 8.9)
Sensitivity/specificity approach 0 (−1 to 2) 1 (−2 to 8)
CASP12
Between patient score change 1.6 (−1.4 to 4.7) 1.3 (−3.1 to 5.7)
Sensitivity/specificity approach 0 (−1 to 3) 4 (−3 to 5)
Notes: AMIC not calculated for the DEMQoL using the participant rating of independence at 6 months: For the between patient score change approach as the mean change 
in DEMQoL score for participants rating themselves as a bit more independent was less than the mean change in the group rating themselves as having no change in 
independence. For the sensitivity/specificity approach as Table 5 shows that discriminatory ability of DEMQoL to discriminate between improvers and non-improvers is less 
than chance (area under curve <0.5). Between patient score change: MIC calculated as the difference between the mean change in the group with a response of a bit better/a 
bit more independent and the group with a response of no change on the global change questions. Sensitivity/specificity approach: MIC defined as the change from baseline 
that maximizes the Youden Index (sensitivity + specificity – 1) to discriminate between improvers and non-improvers. Confidence intervals for sensitivity/specificity approach 
estimated using bootstrapping with 1,000 repetitions. IADL scores range from 0 (low function) to 8 (high function). DEMQoL scores range from 28– 112, higher scores 
indicating better quality-of-life. CASP scores for 19 item version range from 0–57 and for 12 item version range from 0–36, with higher scores indicating better quality-of-life. 
Abbreviations: IADL, Lawton Instrumental Activities of Daily Living Score; CASP, Control, Autonomy, Self-realization, and Pleasure Scale.
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Table 7 Participant Clinical Outcomes Summary by Allocated Group
Baseline Mean [SD] 3 Months Mean [SD] 6 Months Mean [SD]
Lawton Instrumental Activities of Daily Living total score
Usual care 5.6 [1.5] (n=46) 5.2 [1.7] (n=41) 4.7 [1.7] (n=38)
PRIDE intervention 5.0 [1.7] (n=46) 4.6 [2.1] (n=37) 4.8 [2.1] (n=35)
EQ-5D-5L health status VAS score
Usual care 73.0 [19.5] (n=45) 73.8 [15.6] (n=41) 75.1 [17.4] (n=38)
PRIDE intervention 70.5 [17.2] (n=46) 68.4 [18.7] (n=37) 67.4 [17.9] (n=34)
DEMQoL total score
Usual care 88.0 [14.3] (n=46) 90.3 [14.1] (n=41) 91.0 [15.0] (n=38)
PRIDE intervention 87.8 [13.5] (n=46) 90.1 [13.7] (n=37) 89.5 [12.7] (n=35)
Geriatric Depression Scale total score
Usual care 3.8 [3.5] (n=46) 3.4 [3.1] (n=41) 3.4 [3.0] (n=38)
PRIDE intervention 4.6 [3.5] (n=46) 4.1 [2.8] (n=37) 3.8 [3.3] (n=35)
Standardized Mini Mental State Exam total score
Usual care 23.6 [3.6] (n=45) 23.7 [3.2] (n=40) 23.4 [3.9] (n=35)
PRIDE intervention 24.3 [4.0] (n=46) 24.4 [3.4] (n=36) 24.2 [4.3] (n=33)
Control, Autonomy, Self-realization, and Pleasure Scale (CASP-19)
Usual care 41.3 [8.6] (n=46) 42.0 [8.3] (n=41) 42.5 [8.8] (n=37)
PRIDE intervention 39.1 [9.7] (n=46) 40.7 [8.9] (n=37) 39.4 [10.1] (n=35)
CASP-12
Usual care 25.8 [5.8] (n=46) 26.5 [6.0] (n=41) 26.7 [6.1] (n=37)
PRIDE intervention 24.6 [6.7] (n=46) 25.8 [6.0] (n=37) 24.6 [7.0] (n=35)
Impact on Participation and Autonomy (IPAQ-O) – Social Relations Sub-ScaleA
Usual care 9.4 [2.9] (n=46) 9.6 [2.4] (n=41) 8.8 [2.4] (n=38)
PRIDE intervention 9.2 [3.2] (n=46) 8.7 [2.6] (n=37) 8.5 [2.7] (n=35)
Positive Psychology Outcome Measure (PPOM)
Total
Usual care 47.9 [9.8] (n=46) 47.5 [9.6] (n=41) 47.4 [10.4] (n=38)
PRIDE intervention 46.6 [10.8] (= 46) 46.3 [10.3] (n=37) 47.6 [7.8] (n=34)
Hope
Usual care 24.4 [5.1] (n=46) 24.9 [4.8] (n=41) 24.3 [5.3] (n=38)
PRIDE intervention 24.3 [5.5] (n=46) 23.8 [5.7] (n=37) 24.3 [3.9] (n=34)
Resilience
Usual care 23.5 [5.4] (n=46) 22.7 [5.6] (n=41) 23.1 [5.8] (n=38)
PRIDE intervention 22.3 [6.0] (n=46) 22.5 [5.3] (n=37) 23.2 [5.5] (n=34)
Social engagement
Number of times in the last 12 weeks met up with friends or family
Usual care 6.9 [5.8] (n=46) 7.7 [5.2] (n=40) 7.4 [4.6] (n=38)
PRIDE intervention 6.3 [4.6] (n=46) 8.3 [6.1] (n=37) 8.1 [6.7] (n=35)
Number of times over the last 12 weeks participated in any leisure activities
Usual care 5.5 [5.2] (n=45) 6.7 [5.4] (n=41) 4.6 [4.4] (n=38)
PRIDE intervention 8.7 [12.0] (n=46) 8.6 [6.9] (n=36) 7.2 [7.0] (n=34)
Notes: AThe response options on the PRIDE CRF for the IPAQ-O were very good, good, fair, poor, and very poor from the original IPAQ rather than amended response 
options for the IPAQ-O (totally agree, partly agree, neither agree nor disagree, disagree, and totally disagree). Items scored as on the original IPAQ to derive the IPAQ-O 
social relations score. IADL scores range from 0 (low function) to 8 (high function). EQ-5D-5L VAS scores range from 0 (worst health can imagine) to 100 (best health can 
imagine). DEMQoL scores range from 28–112, higher scores indicating better quality-of-life. GDS scores ranging from 0–15, with higher scores indicating more severe 
depression. sMMSE scores range from 0–30, with a lower score indicating more cognitive impairment. CASP: for 19 item version scores range from 0–57 and for 12 item 
version scores range from 0–36, with higher scores indicating better quality-of-life. IPAQ-O social relations subscale scores range from 5–25, with higher score indicating 
more restriction in participation. PPOM total scores range from 0–64 and subscale scores range from 0–32, higher scores indicate better wellbeing.
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Conclusion
This study demonstrated that it is feasible to recruit to and 
carry out a multi-center trial of an individually tailored man-
ualized PRIDE intervention in community-dwelling people 
who have mild dementia. The intervention was well received 
with a high completion rate and the outcome measures were 
completed to a high standard. Although measurable clinical 
benefit of the PRIDE intervention is not clear at present, 
a future large scale RCT has the potential to provide evidence 
of clinical and cost effectiveness. PRIDE is a relatively low- 
resourced 3-session intervention that is easy to deliver, and 
has scope to be scaled up across the health and social care 
services. The PRIDE web-application for tailoring towards 
those who have become seriously isolated during the current 
COVID-19 epidemic is an avenue for future study.
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